Temozolomide and SCH66336 for Recurrent Glioblastoma Multiforme
Completed · Phase 2
Conditions studied: Glioblastoma Multiforme
In brief
This study will combine the chemotherapy agent temozolomide with the investigational drug SCH66336 (an agent which interferes with new cell growth). Patients will be treated with oral temozolomide on days 1-5 and oral SCH66336 on days 8-28 every 28 days.
Key facts
- Study ID
- NCT00038493
- Run by
- M.D. Anderson Cancer Center
- People needed
- 23
- Starts
- 2001-09-21
- Expected to finish
- 2005-08-01
- Last updated by the study team
- 2018-10-29
Who can join
Age: 18 and older. Sex: any. Healthy volunteers: not accepted.
Where it is running
- UTMD Anderson Cancer Center — Houston, Texas, United States
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.